Janoshik result on a Xianning tirzepatide lot lands 1.3 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Harriet Oduya
Page 6 of 10 of this archive, newest first.
Archive — page 6
192 piecesA design note on withdrawal trials, and why the run-in matters
The regain trajectories, arm by arm, with the estimands named.
A year after stopping: what the trials found at the far end
The variance around the mean regain trajectory is large and unexplained, exactly as it is for the weight loss.
STEP 3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Falling ferritin is not always falling iron
Three different explanations for the same abnormal number, and how to tell them apart.
The supply gap as a clinical event
The trials studied planned withdrawal. Almost nobody stops that way.
TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
When a better instrument changes the answer rather than the confidence
Calibration drift is real, unremarkable, and the reason serious laboratories run internal standards.
The shortage years, and what they taught about interruption
The trials studied planned withdrawal. Almost nobody stops that way.
Why a dead-clean sterile filter can pass pyrogen straight through
Three compendial method families are in routine use and a fourth, based on a recombinant enzyme rather than crab lysate, is now compendial in its own right.
PeptideMeter result on a Hangzhou exenatide lot lands 3.5 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
Medutest result on a Nantong orforglipron lot lands 2.6 points below the supplier’s figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
PeptideMeter result on a Wuxi cagrilintide lot lands 2.5 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Independent analysis puts a SGN liraglutide lot at 97.4%, against 93.3% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
Two documents, two disciplines: purity and sterility are not the same trade
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
The precision question nobody puts to a body-composition report
A body-composition report gives four decimal places and no confidence interval. That is the whole difficulty in one sentence.
The precision question nobody puts to a body-composition report
A body-composition report gives four decimal places and no confidence interval. That is the whole difficulty in one sentence.
STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What TRIUMPH-3 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Why a dead-clean sterile filter can pass pyrogen straight through
The limit for a parenteral product is calculable from the dose and the body weight in two lines. Almost nobody in this trade performs the calculation.